ClinicalTrials.gg
WithdrawnNCT01381640Updated Jul 6, 2016

A Study to Compare Two Paracetamol Tablets

A Phase 1 interventional study of Marketed paracetamol and Experimental paracetamol formulation in Healthy Subjects, sponsored by GlaxoSmithKline. Withdrawn at 2 sites in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-06.

Sponsored by GlaxoSmithKline · Phase 1 and Interventional

Why this study was withdrawn
Study was cancelled prior to enrolling any subjects.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a single dose pharmacoscintigraphic study investigating the differences in paracetamol absorption between two formulations.

02

Conditions studied

  • Healthy Subjects

Keywords

  • paracetamol
  • healthy volunteer
  • pharmacoscintography
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy male subjects who are in good general health
  • Have not exceeded the limits of total radiation exposure (5mSv) allowed in any 12 month period
05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Marketed paracetamol

    Marketed formulation

    Drug: Marketed paracetamol

  • Experimental
    Experimental paracetamol formulation

    Experimental formulation

    Drug: Experimental paracetamol formulation

Interventions

06

What researchers measure

Primary outcomes

  1. Time of onset and completion of disintegration based on release of radiolabeled markers in a fed condition

    Time frame: Baseline to 12 hours post dosing

Secondary outcomes

  1. To assess the gastrointestinal transit by qualitative scintigraphic analysis

    Time frame: Baseline to 12 hours post dosing

07

Study locations

2 sites
  • BIO-IMAGES Research Ltd.
    Glasgow, Scotland G63 0BX, United Kingdom
  • Bio-Images
    Glasgow, Scotland G63 0BX, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2011
First posted
Jun 27, 2011
Start
Apr 2010
Primary completionEst.
May 2010
CompletionEst.
May 2010
Last update
Jul 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01381640
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Apr 2010
Primary completion
May 2010 (estimated)
Completion
May 2010 (estimated)
Last update
Jul 6, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion